Based on the result of our previous study showing better overall survival ( OS ) at the lower dose ( 0.2 g ) of immunomodulator Z-100 than higher dose ( 40 g ) in patients with locally advanced cervical cancer who received radiotherapy , we conducted a placebo-controlled double-blind randomized trial .